Can Fite Biofarma (Can Fite Biofarma) EV-to-EBIT : -0.24 (As of May. 14, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Can Fite Biofarma's Enterprise Value is $1.96 Mil. Can Fite Biofarma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.20 Mil. Therefore, Can Fite Biofarma's EV-to-EBIT for today is -0.24.

The historical rank and industry rank for Can Fite Biofarma's EV-to-EBIT or its related term are showing as below:

CANF' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.63 Med: -2.05 Max: 0.55
Current: -0.24

During the past 13 years, the highest EV-to-EBIT of Can Fite Biofarma was 0.55. The lowest was -9.63. And the median was -2.05.

CANF's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 9.44 vs CANF: -0.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Can Fite Biofarma's Enterprise Value for the quarter that ended in Dec. 2023 was $1.09 Mil. Can Fite Biofarma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.20 Mil. Can Fite Biofarma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -751.74%.

Can Fite Biofarma EV-to-EBIT Historical Data

The historical data trend for Can Fite Biofarma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma EV-to-EBIT Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-0.77

-1.17

-1.02

-1.04

-0.07

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-1.04	0.30	-0.32	-0.31	-0.07

Competitive Comparison of Can Fite Biofarma's EV-to-EBIT

For the Biotechnology subindustry, Can Fite Biofarma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's EV-to-EBIT falls into.

Can Fite Biofarma EV-to-EBIT Calculation

Can Fite Biofarma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1.955	/	-8.195
	=	-0.24

Can Fite Biofarma's current Enterprise Value is $1.96 Mil.
Can Fite Biofarma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.20 Mil.

Can Fite Biofarma (AMEX:CANF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Can Fite Biofarma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-8.195	/	1.090138
	=	-751.74 %

Can Fite Biofarma's Enterprise Value for the quarter that ended in Dec. 2023 was $1.09 Mil.
Can Fite Biofarma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.20 Mil.

Can Fite Biofarma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).